Literature DB >> 29263079

Impact of Real-Time Therapeutic Drug Monitoring on the Prescription of Antibiotics in Burn Patients Requiring Admission to the Intensive Care Unit.

P Voirol1,2, Y-A Que3, A Fournier1,2, P Eggimann4, O Pantet4, J L Pagani4, E Dupuis-Lozeron5, A Pannatier1, F Sadeghipour1,2.   

Abstract

As pharmacokinetics after burn trauma are difficult to predict, we conducted a 3-year prospective, monocentric, randomized, controlled trial to determine the extent of under- and overdosing of antibiotics and further evaluate the impact of systematic therapeutic drug monitoring (TDM) with same-day real-time dose adaptation to reach and maintain antibiotic concentrations within the therapeutic range. Forty-five consecutive burn patients treated with antibiotics were prospectively screened. Forty fulfilled the inclusion criteria; after one patient refused to participate and one withdrew consent, 19 were randomly assigned to an intervention group (patients with real-time antibiotic concentration determination and subsequent adaptations) and 19 were randomly assigned to a standard-of-care group (patients with antibiotic administration at the physician's discretion without real-time TDM). Seventy-three infection episodes were analyzed. Before the intervention, only 46/82 (56%) initial trough concentrations fell within the range. There was no difference between groups in the initial trough concentrations (adjusted hazard ratio = 1.39 [95% confidence interval {CI}, 0.81 to 2.39], P = 0.227) or the time to reach the target. However, thanks to real-time dose adjustments, the trough concentrations of the intervention group remained more within the predefined range (57/77 [74.0%] versus 48/85 [56.5%]; adjusted odd ratio [OR] = 2.34 [95% CI, 1.17 to 4.81], P = 0.018), more days were spent within the target range (193 days/297 days on antibiotics [65.0%] versus 171 days/311 days in antibiotics [55.0%]; adjusted OR = 1.64 [95% CI, 1.16 to 2.32], P = 0.005), and fewer results were below the target trough concentrations (25/118 [21.2%] versus 44/126 [34.9%]; adjusted OR = 0.47 [95% CI, 0.26 to 0.87], P = 0.015). No difference in infection outcomes was observed between the study groups. Systematic TDM with same-day real-time dose adaptation was effective in reaching and maintaining therapeutic antibiotic concentrations in infected burn patients, which prevented both over- and underdosing. A larger multicentric study is needed to further evaluate the impact of this strategy on infection outcomes and the emergence of antibiotic resistance during long-term burn treatment. (This study was registered with the ClinicalTrials.gov platform under registration no. NCT01965340 on 27 September 2013.).
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  antibiotics; burn patients; pharmacokinetics; therapeutic drug monitoring

Mesh:

Substances:

Year:  2018        PMID: 29263079      PMCID: PMC5826126          DOI: 10.1128/AAC.01818-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

Review 1.  Infection prevention and treatment in patients with major burn injuries.

Authors:  G Rowley-Conwy
Journal:  Nurs Stand       Date:  2010 Oct 20-26

2.  Prediction of multiple infections after severe burn trauma: a prospective cohort study.

Authors:  Shuangchun Yan; Amy Tsurumi; Yok-Ai Que; Colleen M Ryan; Arunava Bandyopadhaya; Alexander A Morgan; Patrick J Flaherty; Ronald G Tompkins; Laurence G Rahme
Journal:  Ann Surg       Date:  2015-04       Impact factor: 12.969

3.  Standardizing the diagnosis of inhalation injury using a descriptive score based on mucosal injury criteria.

Authors:  Christos Ikonomidis; Florian Lang; Alexandre Radu; Mette M Berger
Journal:  Burns       Date:  2012-02-19       Impact factor: 2.744

4.  Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.

Authors:  Anne Fournier; Philippe Eggimann; Jean-Luc Pagani; Jean-Pierre Revelly; Laurent A Decosterd; Oscar Marchetti; André Pannatier; Pierre Voirol; Yok-Ai Que
Journal:  Burns       Date:  2015-02-10       Impact factor: 2.744

Review 5.  Burn wound infections.

Authors:  Deirdre Church; Sameer Elsayed; Owen Reid; Brent Winston; Robert Lindsay
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

6.  Augmented renal clearance--an evolving risk factor to consider during the treatment with vancomycin.

Authors:  R Minkutė; V Briedis; R Steponavičiūtė; A Vitkauskienė; R Mačiulaitis
Journal:  J Clin Pharm Ther       Date:  2013-08-08       Impact factor: 2.512

7.  Cause of death and correlation with autopsy findings in burns patients.

Authors:  P Krishnan; Q Frew; A Green; R Martin; P Dziewulski
Journal:  Burns       Date:  2012-11-06       Impact factor: 2.744

8.  Pseudomonas aeruginosa acquisition on an intensive care unit: relationship between antibiotic selective pressure and patients' environment.

Authors:  Alexandre Boyer; Adélaïde Doussau; Rodolphe Thiébault; Anne Gaëlle Venier; Van Tran; Hélène Boulestreau; Cécile Bébéar; Frédéric Vargas; Gilles Hilbert; Didier Gruson; Anne Marie Rogues
Journal:  Crit Care       Date:  2011-02-09       Impact factor: 9.097

Review 9.  How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?

Authors:  Gloria Wong; Fekade Bruck Sime; Jeffrey Lipman; Jason A Roberts
Journal:  BMC Infect Dis       Date:  2014-11-28       Impact factor: 3.090

Review 10.  Antibiotic stewardship in the intensive care unit.

Authors:  Charles-Edouard Luyt; Nicolas Bréchot; Jean-Louis Trouillet; Jean Chastre
Journal:  Crit Care       Date:  2014-08-13       Impact factor: 9.097

View more
  9 in total

1.  Electrochemical Aptamer-Based Sensors for Improved Therapeutic Drug Monitoring and High-Precision, Feedback-Controlled Drug Delivery.

Authors:  Philippe Dauphin-Ducharme; Kyungae Yang; Netzahualcóyotl Arroyo-Currás; Kyle L Ploense; Yameng Zhang; Julian Gerson; Martin Kurnik; Tod E Kippin; Milan N Stojanovic; Kevin W Plaxco
Journal:  ACS Sens       Date:  2019-10-15       Impact factor: 7.711

2.  Is Alternate-Day Therapeutic Drug Monitoring in the Intensive Care Unit Not Intensive Enough?

Authors:  Parviz Sorooshian; Timothy A C Snow
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

3.  Reply to Sorooshian and Snow, "Is Alternate-Day Therapeutic Drug Monitoring in the Intensive Care Unit Not Intensive Enough?"

Authors:  A Fournier; P Eggimann; O Pantet; J L Pagani; E Dupuis-Lozeron; A Pannatier; F Sadeghipour; P Voirol; Y-A Que
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

4.  Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center.

Authors:  Anne Fournier; Sylvain Goutelle; Yok-Ai Que; Philippe Eggimann; Olivier Pantet; Farshid Sadeghipour; Pierre Voirol; Chantal Csajka
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

5.  A systematic review of the effect of therapeutic drug monitoring on patient health outcomes during treatment with penicillins.

Authors:  Timothy Luxton; Natalie King; Christoph Wälti; Lars Jeuken; Jonathan Sandoe
Journal:  J Antimicrob Chemother       Date:  2022-05-29       Impact factor: 5.758

6.  Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study.

Authors:  Erin F Barreto; Andrew D Rule; Mohammad H Alshaer; Jason A Roberts; Mohd Hafiz Abdul Aziz; Marc H Scheetz; Kristin C Mara; Paul J Jannetto; Ognjen Gajic; John C O'Horo; Kasey R Boehmer
Journal:  Implement Sci Commun       Date:  2021-03-24

Review 7.  Carbapenem Therapeutic Drug Monitoring in Critically Ill Adult Patients and Clinical Outcomes: A Systematic Review with Meta-Analysis.

Authors:  Sharon Lechtig-Wasserman; Hans Liebisch-Rey; Nicolas Diaz-Pinilla; Jhosep Blanco; Yuli-Viviana Fuentes-Barreiro; Rosa-Helena Bustos
Journal:  Antibiotics (Basel)       Date:  2021-02-10

8.  Therapeutic drug monitoring of cefepime in a non-critically ill population: retrospective assessment and potential role for model-based dosing.

Authors:  Véronique Suttels; Pascal André; Yann Thoma; François Veuve; Laurent Decosterd; Benoît Guery; Thierry Buclin
Journal:  JAC Antimicrob Resist       Date:  2022-04-21

Review 9.  β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value.

Authors:  Thomas J Dilworth; Lucas T Schulz; Scott T Micek; Marin H Kollef; Warren E Rose
Journal:  Crit Care Explor       Date:  2022-07-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.